Eli Lilly and Company announced that Mounjaro KwikPen (tirzepatide) is now available across India in all doses. Approved by the Central Drugs Standard Control Organisation (CDSCO), Mounjaro KwikPen, a prescription-based, once-weekly treatment, offers a convenient way for patients to administer their medication. Mounjaro is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of:
- Type 2 diabetes
- Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.
Mounjaro KwikPen is a multi-dose, single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing healthcare professionals to personalise treatment plans to better suit individual patient needs.
Each Mounjaro KwikPen contains four full doses. Available strengths and prices are listed below.
| Dose Strength | Maximum Retail Price (per month) |
|---|---|
| 2.5 mg KwikPen | ₹14,000 |
| 5 mg KwikPen | ₹17,500 |
| 7.5 mg KwikPen | ₹22,000 |
| 10 mg KwikPen | ₹22,000 |
| 12.5 mg KwikPen | ₹27,500 |
| 15 mg KwikPen | ₹27,500 |
Mounjaro is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. It is not approved for—and must not be used for—cosmetic weight loss. Patients are advised to consult their healthcare professional to determine whether Mounjaro® is appropriate for their individual needs.
Mounjaro (tirzepatide) is a single molecule, once-weekly, prescription-only medicine that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones. In a glucose-dependent manner, Mounjaro (tirzepatide) improves first-phase and second-phase insulin secretion and reduces glucagon levels; it also improves insulin sensitivity and delays gastric emptying. GIP receptors and GLP-1 receptors are both expressed in important areas of the brain that regulate appetite. Mounjaro (tirzepatide) reduces body weight and decreases fat mass by regulating appetite; moreover, Mounjaro (tirzepatide) has been demonstrated to regulate lipid utilisation. Mounjaro (tirzepatide) has already had a tremendous impact on millions of people living with type 2 diabetes and obesity, respectively.